FDA

Where Things Stand: FDA Halting Use Of Some Monoclonal Antibodies Treatments Bursts GOP’s Anti-Vax Bubble
This is your TPM evening briefing.

But some Republicans are already using the Biden administration’s new, common sense decision to pour gasoline on their baseless federal overreach fights.

The Food and Drug Administration removed two monoclonal antibody therapies from its list of approved treatments for COVID-19 this week, at least temporarily. Citing clinical data, the FDA said in a statement that it has found two of the treatments “are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States.” HHS sent out a letter to state officials this week, alerting them that the federal government would stop handing out the treatments made by Regeneron Pharmaceuticals and Eli Lilly to states for now, according to the Washington Post which obtained a copy of the letter.

Read More
MEAT
ORLANDO, FLORIDA, UNITED STATES - 2021/04/10: Johnson & Johnson COVID-19 vial and box seen at a vaccination site.Doses of the Johnson & Johnson vaccine are being administered throughout the state of Florida despite a small number of patients who have experienced adverse reactions, including blood clots. (Photo by Paul Hennessy/SOPA Images/LightRocket via Getty Images)
WASHINGTON, DC - AUGUST 23: FDA Commissioner Stephen Hahn looks on as President Donald Trump announces that the Food and Drug Administration is issuing an emergency authorization for blood plasma as a coronavirus treatment during a press conference in James S. Brady Briefing Room at the White House on on August 23, 2020 in Washington, DC. The move by the FDA comes after President Trump accused the FDA of slow-walking the therapy to harm his reelection chances.(Photo by Pete Marovich/Getty Images)
Boxes containing the Moderna COVID-19 vaccine are prepared to be shipped at the McKesson distribution center in Olive Branch, Miss., Sunday, Dec. 20. (AP Photo/Paul Sancya, Pool)
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Reporters:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: